Analyst initiations 9-6-07: MSFT, CRM, TLEO and MFE

Published: September 6, 2007, 7:13 am

Tags: analyst, astrazeneca, azn, bfc financial, bfcfinancial, bff, capital product partners, capitalproductpartners, cplp, crm, firm, glaxosmithkline, gsk, initiation, lulu, lululemon, mcafee, mfe, microsoft, msft, novartis, nvs, rhhby, roche holding, rocheholding, salesforce com, sanof

Filed under: Analyst reports, Microsoft (MSFT), Analyst initiations, salesforce.com inc (CRM), Zoltek Co (ZOLT)MOST NOTEWORTHY: European pharmaceuticals, Microsoft, Salesforce.com, Taleo and McAfee were today's noteworthy initiations: UBS resumed coverage of Novartis AG (NYSE: NVS) with a Buy rating and AstraZeneca (NYSE: AZN), Roche Holding (OTC: RHHBY), Sanofi-Aventis (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK) with Neutral ratings. Deutsche Bank believes new product leverage can bring upside to consensus operating margin expectations at Microsoft Corporation (NASDAQ: MSFT) and they view shares as attractively valued given its growth profile. The firm started shares with a Buy rating and $33 target. Keybanc initiated shares of Salesforce.com (NYSE: CRM) with a Hold rating and sees slowing growth rates for revenue and net subscriber additions throughout the remainder of FY08 and beyond and thinks investor expectations are too high. Keybanc also started shares of

[ Full article ]

Blog link

Comments